This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

POSTERS AND E-POSTER PRESENTATIONS

 

Friday February 28, 2020

TOPIC

Number

ABSTRACT TITLE

 Author(s)

Biomedical Research CHC - P - 001 Identifying the Role Played by the Poly(rC)-Binding Protein 2 (PCBP2) in the HCV Life Cycle Sophie E Cousineau
Biomedical Research CHC - P - 002 The role of community-based specialized pharmacies in provincial hepatitis C elimination Gaurav Arora
Biomedical Research CHC - P - 003 Understanding NK and T cell Dysfunction in Chronic HCV patients with Advanced Liver Fibrosis by Immunoprofiling of Inhibitory Receptors. Chisom Okwor
Biomedical Research CHC - P - 004 Precision-Cut Liver Slice (PCLS) culture: a model to examine HCV interactions with the liver microenvironment Catia Taniela Perciani
Biomedical Research CHC - P - 005 Hepatitis C virus exploits cyclophilin A to evade PKR- and IRF1-dependent antiviral responses Che C Colpitts
Biomedical Research CHC - P - 006 Neutrophils are the major producers of the pro-fibrogenic cytokine IL-17A in non-alcoholic fatty liver disease (NAFLD) Mohamed N. Abdelnabi
Biomedical Research CHC - P - 007 Quantifying the relative contributions of the three roles of miR-122 in the HCV life cycle Marylin Rheault
Biomedical Research CHC - P - 008 Immune Restoration of Hepatitis C Virus-specific T cells following Direct Acting Antiviral Therapy in Acute Hepatitis C Virus- infected Patients Julia Casey
Biomedical Research CHC - P - 009 The Use of Oncolytic Measles-Based Vectors for Targeted Treatment of HCV-Induced Liver Cancer Ching-Hsuan Julia Liu
Biomedical Research CHC - P - 010 HCV 3’UTR and the Host Helicases DDX1 and DDX3X Vanessa Meier-Stephenson
Social, Cultural, Environmental and Population Health Research CHC - P - 011 Integrating community-based recruitment with data linkage to inform and enhance scale-up of HCV treatment among people who inject drugs in Canada: The VCCC study protocol. Stine Bordier Hoj
Social, Cultural, Environmental and Population Health Research CHC - P - 012 Increasing hepatitis C screening & new diagnoses in 10 British Columbia Provincial Correctional Centres from 2010-2019 Sofia Bartlett
Social, Cultural, Environmental and Population Health Research CHC - P - 013 Diversity of detention patterns among people who inject drugs and the associated risk with incident hepatitis C virus (HCV) infection: Implications for hepatitis C prevention Andreea Adelina Artenie
Social, Cultural, Environmental and Population Health Research CHC - P - 014 Anticipated timing of elimination of hepatitis C virus in Canada’s four most populous provinces Jordan Feld
Social, Cultural, Environmental and Population Health Research CHC - P - 015 Gender-specific associations between psychological distress and HCV risk behaviours among people who inject drugs in Montreal Nanor Minoyan
Social, Cultural, Environmental and Population Health Research CHC - P - 016 Estimation of an individual-level deprivation index for HIV/HCV coinfected persons Adam Palayew
Social, Cultural, Environmental and Population Health Research CHC - P - 017 Geographic distribution of people living with hepatitis C in British Columbia: an application of latent class analysis and disease mapping Zahid A Butt
Social, Cultural, Environmental and Population Health Research CHC - P - 018 Hepatitis C Awareness, Screening and Linkage to Care Among the Pakistani Community in Montreal: The Aagahi Project Stephanie Toigo
Social, Cultural, Environmental and Population Health Research CHC - P - 019 Mapping the Immigrant population and cultural and community organizations to inform community outreach and HCV microelimination efforts in Montreal Berson Augustin
Social, Cultural, Environmental and Population Health Research CHC - P - 020 Reviewing, appraising, and synthesizing observational data to inform dynamic mathematical modeling of HCV and HIV transmission among people who inject drugs in Montréal, Canada Charlotte Laniece Delaunay
Social, Cultural, Environmental and Population Health Research CHC - P - 021 Potential impacts of closing low-threshold Overdose Prevention Sites on HCV and HIV prevention efforts in Toronto, Canada Gillian Kolla
Social, Cultural, Environmental and Population Health Research CHC - P - 022 Perceptions of HCV Treatment and Reinfection Risk among HIV-Positive Men who have Sex with Men in Sydney, Australia: A Qualitative Study Alison D Marshall
Social, Cultural, Environmental and Population Health Research CHC - P - 023 Toward the elimination of HCV vertical transmission: A targeted, patient-informed hepatitis C engagement program in persons who use drugs in their child bearing years in southern New Brunswick Kate Harland
Social, Cultural, Environmental and Population Health Research CHC - P - 024 Peer led point-of-care testing: The role of Atlantic Canada’s first overdose prevention site in hepatitis C elimination Matthew Bonn
Social, Cultural, Environmental and Population Health Research CHC - P - 025 Strengthening Canada’s hepatitis C response by producing culturally and linguistically-relevant resources for Canadian immigrants and their service providers Fozia Tanveer
Social, Cultural, Environmental and Population Health Research CHC - P - 026 Estimating Direct-Acting Antiviral impact among key populations in Ontario: a research proposal Zoe R Greenwald
Social, Cultural, Environmental and Population Health Research CHC - P - 028 HCV: The Neurocognitive Impact in the Overdose Epidemic Douglas Laird
Clinical Research CHC - P - 029 Non-invasive surrogates of portal hypertension predict decompensation in obese patients with compensated advanced chronic liver disease Giada Sebastiani
Clinical Research CHC - P - 030 Impact of Treatment With Tenofovir Alafenamide (TAF) or Tenofovir Disoproxil Fumarate (TDF) on Hepatocellular Carcinoma (HCC) Incidence in Patients with Chronic Hepatitis B (CHB) Scott K Fung
Clinical Research CHC - P - 031 Universal HCV and HIV screening in an Emergency Room – fewer new cases than expected Valerie Martel-Laferriere
Clinical Research CHC - P - 032 DAA Treatment Uptake or Outcomes are Not Effected by Alcohol Use: A CANUHC Analysis Curtis Cooper
Health Services Research CHC - P - 033 Can we afford to screen and treat hepatitis C virus (HCV) infection in Canada? Latest insight from a Canadian policy model – A province-by-province analysis William WL Wong
Health Services Research CHC - P - 034 A Review of Public Reimbursement Criteria for Pan-Genotypic HCV DAAs in Canada Robert Milenkovski
Health Services Research CHC - P - 035 Pilot peer-led hepatitis C screening leads to high testing uptake and rapid treatment initiation in a women’s residential recovery facility Mia  Biondi
Health Services Research CHC - P - 036 Disparities in health utilities among hepatitis C patients receiving care in different settings Yasmin Saeed
Health Services Research CHC - P - 037 Health Services Impact Analysis of Simplifying HCV Diagnosis and Treatment Decision in Canada Robert Milenkovski
Health Services Research CHC - P - 038 Hepatitis C (HCV) Re-engagement Strategy after Loss to Follow-up Gisela L P Macphail
Health Services Research CHC - P - 039 Building Capacity in Hepatitis C Management: Progress and outcomes from the ECHO Ontario Liver program Morven Cunningham 
Health Services Research CHC - P - 040 Examining patient complexity in ECHO: results from a hepatitis C telementoring education program Hemant Shah
Health Services Research CHC - P - 041 The Canadian Network on Hepatitis C Virtual Cascade of Care Cohort (VCCC) Feasibility Study - Saskatchewan Component Kehinde Ametepee

 

Saturday FEBRUARY 29, 2020

TOPIC

NUMBER

ABSTRACT TITLE

 AUTHOR(S) 

Viral Hepatitis

CLM - P - 124 REAL-WORLD DRUG RESISTANCE PROFILE OF HEPATITIS C PATIENTS WHO FAILED DIRECT-ACTING ANTIVIRALS – SHARED Anita YM Howe
Viral Hepatitis CLM - P - 125 Hepatitis C Positive Organ Transplantation to Negative Recipients at a Multiorgan Canadian Transplant Centre: Ready for Prime Time Waleed Alghamdi
Viral Hepatitis CLM - P - 126 Reducing the burden of hepatitis C-related complications through genomics-guided treatment optimization Catrina M Loucks
Viral Hepatitis CLM - P - 127 Outcomes of Hepatitis C treatment are similar in Canadian Indigenous people compared to non-Indigenous patients Susan Christenson
Viral Hepatitis CLM - P - 128 Treatment differential in HCV treatment prescribers in British Columbia over time Emilia Clementi
Viral Hepatitis CLM - P - 129 CHARACTERISTICS OF RESISTANCE-ASSOCIATED SUBSTITUTIONS IN “UNUSUAL” HEPATITIS C VIRUS (HCV) SUBTYPES Anita Howe
Viral Hepatitis CLM - P - 130 Comparison of hepatitis C prenatal screening approaches between provinces: Seroprevalence and infection rates in universal vs risk-based screening Mia Biondi
Viral Hepatitis CLM - P - 131 Factors associated with on-demand HCV screening among Canadian provincial inmates Camille Dussault
Viral Hepatitis CLM - P - 132 Real World Single Centre Experience on the Efficacy of Stopping Long Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B (CHB). Hassan Azhari
Viral Hepatitis CLM - P - 133 Reticulon-3 Modulates the loading of Replication Competent Hepatitis C Virus Molecules for Release Inside Infectious Exosomes. Jingjing Li
Viral Hepatitis CLM - P - 134 Birth cohort screening for hepatitis C during routine outpatient endoscopy Jennifer A Flemming
Viral Hepatitis CLM - P - 135 Mechanistic analysis of miR-122 promotion of HCV replication Rasika Kunden
Viral Hepatitis CLM - P - 136 Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection Jordan J Feld
Viral Hepatitis CLM - P - 137 Prenatal Hepatitis C Screening and Diagnoses in British Columbia, 2008-2018 Margo Pearce
Viral Hepatitis CLM - P - 138 Targeting Hepatitis B virus cccDNA in vitro Simmone D'souza
Viral Hepatitis CLM - P - 139 Exploiting cccDNA’s structural features to find new HBV targets Vanessa Meier-Stephenson
Viral Hepatitis CLM - P - 140 NAFLD and Alcohol Affect Long-term Liver Fibrosis Regression Post-HCV Eradication Alnoor Ramji
Viral Hepatitis CLM - P - 142 Ethnic disparities in the risk of hepatitis C virus-related diabetes in a large population-based cohort in Canada Dahn Jeong
Viral Hepatitis CLM - P - 143 Natural history of cirrhotic people who use drugs (PWUD) following successful HCV therapy in the direct-acting antiviral (DAA) era Lauren Jones
Viral Hepatitis CLM - P - 144 Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment Naveed Z Janjua
Viral Hepatitis CLM - P - 145 Current Opioid Agonist Therapy is associated with hepatitis C virus treatment uptake among People Who Inject Drugs in a population based data linkage study Sofia Bartlett
Viral Hepatitis CLM - P - 146 Syndemic of viral co-infections and incident end-stage renal disease Dahn Jeong
Viral Hepatitis CLM - P - 147 GENOTYPE MISCLASSIFICATION AND ITS IMPACT ON TREATMENT CHOICES, OUTCOMES AND DRUG RESISTANCE Anita Howe
Viral Hepatitis CLM - P - 148 Association between prescription opioids and Hepatitis C virus seroconversion among people who use injection drugs in British Columbia James Wilton
Viral Hepatitis CLM - P - 149 Evidence for a striking failure in diagnosis and linkage to care for hepatitis C-infected patients in Alberta, Canada Hassan Azhari
Viral Hepatitis CLM - P - 150 Prescribing Trends of Direct Acting Antivirals (DAAs) for the Treatment of Hepatitis C in Ontario Mary Guyton
Viral Hepatitis CLM - P - 151 CD8 T cell dysfunction and cancer development in a murine model of liver fibrosis Jood A Madani
Viral Hepatitis CLM - P - 152 Early peg-interferon-related ALT flares of high magnitude lead to HBsAg decline and loss. A study of 639 chronic hepatitis B patients. Hannah SJ Choi
Viral Hepatitis CLM - P - 153 Population-level hepatitis C cascade of care among men who have sex with men in British Columbia, Canada Naveed Z Janjua
Viral Hepatitis CLM - P - 155 DIFFERENTIAL HEPATITIS B VIRUS (HBV) AND HEPATITIS D VIRUS (HDV) SPECIFIC T- CELL RESPONSE IN HDV RNA POSITIVE AND NEGATIVE PATIENTS Shivali Joshi
Viral Hepatitis CLM - P - 156 Differences in Surveillance for HCC in HIV infected patients with and without HCV/HBV coinfection: insights from LIVEHIV Cohort. Alshaima Alhinai
Viral Hepatitis CLM - P - 158 Transaminase flares during HBsAg reduction to < 1 IU/mL are correlated with the establishment of virologic control and functional cure of HBV following NAP-based combination therapy Michel Bazinet 
Viral Hepatitis CLM - P - 159 Hepatitis C virus reinfection after successful treatment with direct acting antiviral therapy in British Columbia Naveed Zafar Janjua
Viral Hepatitis CLM - P - 160 Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users: The GRAND PLAN study Brian Conway
Viral Hepatitis CLM - P - 161 Overdose events among active drug users successfully treated for HCV:  the impact of homelessness Tianna Magel
Viral Hepatitis CLM - P - 162 Prevalence and genotype of occult hepatitis B infection in a human immunodeficiency virus (HIV) positive patient cohort in Gondar, Ethiopia Nishi H. Patel
Viral Hepatitis CLM - P - 163 Trends in hepatocellular carcinoma survival among individuals infected with HBV and/or HCV in British Columbia, Canada (2001-2016) James Wilton
Viral Hepatitis CLM - P - 164 A population-level latent class analysis of people living with hepatitis C virus for effective program planning and health care resource distribution Emilia Clementi
Viral Hepatitis CLM - P - 165 Sofosbuvir/velpatasvir (S/V) for the treatment of chronic HCV in active drug users: The CHIME study Brian Conway
Viral Hepatitis CLM - P - 167 Who are the real transformational leaders? From peer educators to peer navigators Martin Page
Viral Hepatitis CLM - P - 168 Transcriptomic analyses of the immune response during HCV re-infection Sabrina Mazouz
Viral Hepatitis CLM - P - 169 Association between hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A meta-analytic synthesis of observational studies Mohammad Adil
Viral Hepatitis CLM - P - 170 MicroRNA-122 promotion of Hepatitis C Virus translation is important early in the HCV infection cycle to initiate an HCV infection. Mamata Panigrahi
Viral Hepatitis CLM - P - 171 Improved Linkage to Care by Targeting HCV RNA(+) Persons in the BC-HCV Network Alnoor Ramji
Viral Hepatitis CLM - P - 172 The Impact of Small RNA Binding on Hepatitis C Virus Replication via Structural Changes within the 5’ Untranslated Region Michael Palmer
Viral Hepatitis CLM - P - 173 Can Neurological Weakness be the First presentation of chronic hepatitis in Immunosuppressed population? Case Report and Literature Review May Alzahrani
General Hepatology CLM - E- 102 HYPOFIBRINOLYSIS AS A CONTRIBUTING MECHANISM OF CIRRHOTIC PORTAL VEIN THROMBOSIS AS EVIDENCED BY ROTATIONAL THROMBOELASTOMETRY (ROTEM) Steven Pi
Biomedical Research CLM - E- 101 Identifying the Role Played by the Poly(rC)-Binding Protein 2 (PCBP2) in the HCV Life Cycle Sophie E Cousineau
General Hepatology CLM - E- 103 “FIB-4 FIRST” STRATEGY IN A NAFLD ASSESSMENT PATHWAY FOR HIV MONO-INFECTED PATIENTS Adriana Cervo
General Hepatology CLM - E- 104 Combined Regimen Immune Checkpoint Inhibitor-Associated Hepatitis: Experience from a North American Multicenter Cohort Matthew Kent Smith

General Hepatology

                                                                                                       

CLM - E- 105 Simple Non-Invasive Prediction of Advanced Fibrosis in NAFLD – A Stepwise Approach and External Validation Study to Reduce Indeterminates and Biopsy Keyur Patel 

Sunday march 1, 2020

TOPIC

NUMBER

TITLE

 AUTHOR(S)

General Hepatology CLM - P -  179 Modelling Non-alcoholic Fatty Liver Disease Burden in Canada, 2019-2030 Mark Gordon Swain            
General Hepatology CLM - P -  180 Lenvatinib for the first-line treatment of advanced or unresectable hepatocellular carcinoma: a cost-effectiveness analysis from a Canadian perspective Suthakar Sabapathy 
General Hepatology CLM - P -  181 Reducing Length of Stay in Patients Following a Liver Transplant Abdulrhman Alamr
General Hepatology CLM - P -  182 The role of transferrin receptor 1 (Tfr1) in liver iron sensing and systemic iron homeostasis Edouard Charlebois
General Hepatology CLM - P -  183 A New Score Including Anthropometric Measurement for Weight Improved prediction of mortality of adolescents on the liver transplantation waiting list: US Nationwide Study Abdel-Aziz Shaheen
General Hepatology CLM - P -  184 Performance of noninvasive fibrosis tests among NAFLD patients with normal ALT: Data from a large North American primary care NAFLD Pathway Abdel-Aziz Shaheen
General Hepatology CLM - P -  185 Impact of Repeat Transient Elastography within 3 Years on Clinical Management in Chronic Liver Disease Reza Naghdi
General Hepatology CLM - P -  186 Evolution of autoimmune cholangitis and primary sclerosing cholangitis in a pediatric cohort. Julian Hercun
General Hepatology CLM - P -  187 Tolerogenic effect of pregnancy in autoimmune hepatitis Pascal Lapierre
General Hepatology CLM - P -  188 Symptom burden in patients living with Primary Biliary Cholangitis: Indigenous Canadians report significantly higher PBC-40 quality of life scores Surain B Roberts
General Hepatology CLM - P -  189 Assessment of fibrosis and steatosis in patients and healthy volunteers Edward  Tam
General Hepatology CLM - P -  190 Impact of Depression and Antidepressant Use on the Development of Chronic Liver Disease: A Longitudinal UK Population-based Study Abdel-Aziz Shaheen
General Hepatology CLM - P -  191 Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) vs sorafenib (SOR) Wendy Hauck 
General Hepatology CLM - P -  192 Ultrasound Surface and Hepatic Vein nodularity as Predictors of Histologic Advanced Fibrosis in Chronic Liver Disease Maryam Moini
General Hepatology CLM - P -  193 Factors Associated with Vibration Controlled Transient Elastography Failure in a High-Volume North American Liver Clinic Surain B Roberts
General Hepatology CLM - P -  194 Validation of a Hierarchical Algorithm to Define Chronic Liver Disease and Cirrhosis Etiology in Administrative Healthcare Data George Philip
General Hepatology CLM - P -  195 Retrovirus footprint in primary sclerosing cholangitis; APOBEC3 family expression Kiandokht Bashiri
General Hepatology CLM - P -  196 Optimising trial design in late-stage primary biliary cholangitis: Evaluating options for composite clinical endpoint studies C. Fiorella Murillo Perez
General Hepatology CLM - P -  197 Real-world experience with obeticholic acid (OCA) in Canada: A retrospective analysis of primary biliary cholangitis (PBC) patient characteristics and treatment patterns from the Canadian Patient Support Program Aliya Gulamhusein
General Hepatology CLM - P -  198 Metabolic alterations of human liver tissue occurring during biobanking procedures. Valérie-Ann Raymond
General Hepatology CLM - P -  199 Liver Transplantation (LT) for Hepatocellular Carcinoma in Alberta: Patients Assessed for LT in Calgary Wait Longer for Listing and Have Increased Mortality Compared to Those Assessed in Edmonton Alexandra Frolkis
General Hepatology CLM - P -  200 Serum Ferritin is Not Associated with Elevated Elastography Scores in Non-alcoholic Fatty Liver Disease Roberto Trasolini
General Hepatology CLM - P -  201 Test-retest reliability of hepatic venous pressure gradient: a study in 215 patients from the control arms of 17 randomized controlled trials Wayne Bai
General Hepatology CLM - P -  202 Preliminary results of the prevalence of fatty liver disease in the Greater Toronto population Anish Jammu
General Hepatology CLM - P -  203 FINCh: Fibroscan Impact on Non-alcoholic fatty liver disease in Children – using randomized placebo-phase design trial Marie Sara-Pier Piscopo
General Hepatology CLM - P -  205 HEPATIC STEATOSIS PREDICTS FIBROSIS IN LONG-TERM METHOTREXATE USE Marcel Tomaszewski
General Hepatology CLM - P -  207 Validation of FIB-4 Scores and Liver Stiffness Measurements (LSM) by VCTE as Non-Invasive Modalities for Detection of Advanced Fibrosis in NAFLD Patients Magdy Elkhashab
General Hepatology CLM - P -  208 Impact of Depression and Antidepressant Usage on the Clinical Outcomes of Chronic Liver Disease Abdel-Aziz Shaheen
General Hepatology CLM - P -  209 Post-partum Primary Biliary Cholangitis (PBC) after resolution of Intrahepatic Cholestasis of Pregnancy (ICP) in First Nation’s Patients of BC: A Case series Daljeet Singh Chahal
General Hepatology CLM - P -  210 NMR metabolic profiling can help discriminate between normal primary hepatocytes and diverging hepatic cancer cell lines Corentine Goossens
General Hepatology CLM - P -  211 Vitamin D deficiency and its association with clinical outcomes in primary sclerosing cholangitis Aldo J. Montano-Loza
General Hepatology CLM - P -  212 ERYTHROPOIETIC PROTOPORPHYRIA: AN UNUSUAL PRESENTATION OF ADVANCED LIVER FIBROSIS DURING INFANCY Richard A. Schreiber
General Hepatology CLM - P -  213 Histological characterization of muscle and adipose tissue in patients with cirrhosis receiving liver transplant Maryam Ebadi
General Hepatology CLM - P -  214 Role of glutamine in the tumorigenicity of the murine hepatocarcinoma cell line Dt81Hepa1-6. Vincent Tambay
General Hepatology CLM - P -  215 Factors Associated With Dialysis Independence in Patients With Cirrhosis and Acute Kidney Injury Requiring Dialysis: A Population-based Study Peter Wang
General Hepatology CLM - P -  216 FIB4 or NFS can reliably predict fibrosis in sub-groups of NAFLD patients Alnoor Ramji
General Hepatology CLM - P -  217 Prevalence and associated factors of non-alcoholic fatty liver disease in South Asian women with polycystic ovary syndrome: A prospective study using Transient Elastography Mohamed Shengir
General Hepatology CLM - P -  218 Diabetes is associated to the development of hepatic encephalopathy in cirrhotic patients Cristina R Bosoi
General Hepatology CLM - P -  219 Prevalence of Liver Diseases in Referred Patients of Varying Ethnic Backgrounds within the Toronto Liver Centre Magdy Elkhashab
General Hepatology CLM - P -  220 Characteristics and Outcomes of Patients with Primary Sclerosing Cholangitis at a Canadian Tertiary Care Center Harjot Bedi
General Hepatology                                                                                   CLM - P -  221 New insights on the impact of sex on chronic liver disease and hepatic encephalopathy Mariana M. Oliveira